Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients
- 25 November 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 8 (4), 214-219
- https://doi.org/10.1007/s10120-005-0337-4
Abstract
Alterations of the p53 tumor suppressor gene are the most commonly observed genetic abnormalities in many different types of human malignancies. The accumulation of mutant p53 often leads to the production of p53 antibody (p53-Ab) in the sera of patients with various cancers. To evaluate the clinical implications of serum p53-Abs in patients with gastric cancer, we compared p53-Abs with conventional tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9. Serum samples were obtained preoperatively from 40 patients with histologically confirmed gastric adenocarcinoma, including 28 (70%) patients in stage Ia. The serum p53-Abs were assessed by enzyme-linked immunosorbent assay, using a new version of a highly specific, quantitative p53-Abs Kit (MESACUP Kit II). p53-Abs were detected in 6 (15%) of 40 patients with gastric cancer, including 3 patients with early gastric cancer. Seven (17.5%) of the 40 patients were positive for CEA in serum. However, none of 7 patients with high CEA levels were positive for p53-Abs. No significant correlation of p53-Abs with patient age, sex, pathological parameters, tumor markers such as CEA and CA19-9, or poor survival (P = 0.116) was observed. Although we employed the latest version of the p53-Abs Kit, the sensitivity of serum p53-Ab in gastric cancer patients was relatively low. No correlation was found between the presence of p53-Ab and the staging of cancer or survival. However, serum p53-Ab was detectable in patients with gastric cancer even in the early stages of disease. In addition, it may be independent of CEA and CA19-9.Keywords
This publication has 37 references indexed in Scilit:
- Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early‐stage gastric carcinomaScandinavian Journal of Gastroenterology, 2004
- Soluble E-Cadherin is an Independent Pretherapeutic Factor for Long-Term Survival in Gastric CancerJournal of Clinical Oncology, 2003
- Titration of serum p53 antibodies in 1085 patients with various types of malignant tumorsCancer, 2003
- Low presence of p53 abnormalities in H. pylori -infected gastric mucosa and in gastric adenocarcinomaThe Esophagus, 2003
- Dual Role of Serum Soluble E-cadherin as a Biological Marker of Metastatic Development in Gastric CancerScandinavian Journal of Gastroenterology, 2003
- Clinical implications of serum anti-p53 antibodies for patients with gastric carcinomaCancer, 1999
- Anti-p53 Antibodies in Sera of Workers Occupationally Exposed to Vinyl ChlorideJNCI Journal of the National Cancer Institute, 1995
- Multifactorial analysis of p53 alteration in human cancer: A reviewInternational Journal of Cancer, 1994
- Oncogenes and Tumor Suppressor Genes: New Biochemical TestsCritical Reviews in Clinical Laboratory Sciences, 1992
- The p53 tumour suppressor geneNature, 1991